Overview

Effects Of GW679769 On Sleep Onset And Maintenance And Next Day Functioning In Subjects With Primary Insomnia

Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
This study is designed to find the optimal (best) doses of GW679769 that could be given daily to promote sleep onset and maintain sleep during the night without significant next-day thinking impairment and drowsiness in subjects with primary insomnia.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Casopitant